ACIU NASDAQ
AC Immune S.A.
1W: +8.3%
1M: -3.9%
3M: +8.8%
YTD: -18.8%
1Y: -10.2%
3Y: -9.0%
5Y: -60.5%
$2.73
-0.09 (-3.02%)
Weekly Expected Move ±7.3%
$2
$3
$3
$3
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$4M
-86.9% ▼
5Y CAGR: -25.4%
Gross Profit
$4M
+110.1% ▲
Operating Income
-$69M
-31.5% ▼
Net Income
-$67M
-32.1% ▼
EPS (Diluted)
$-0.67
-31.4% ▼
EBITDA
-$63M
-30.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $4M | $15M | $27M | $4M |
| YoY Growth | -100.0% | +0.0% | +276.1% | +84.5% | -86.9% |
| Cost of Revenue | $0 | $0 | $55M | $63M | $0 |
| Gross Profit | $0 | $4M | -$40M | -$35M | $4M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| R&D Expenses | $62M | $60M | $55M | $63M | $54M |
| SG&A Expenses | $11M | $10M | $11M | $11M | $12M |
| Operating Expenses | $79M | $75M | $14M | $17M | $72M |
| Operating Income | -$79M | -$71M | -$54M | -$52M | -$69M |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Expense | $581K | $355K | $176K | $133K | $182K |
| Income Before Tax | -$73M | -$71M | -$54M | -$51M | -$70M |
| Tax Expense | $3K | $13K | $10K | $3K | $0 |
| Net Income | -$73M | -$71M | -$54M | -$51M | -$67M |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1883.0% |
| EPS (Diluted) | $-0.97 | $-0.85 | $-0.64 | $-0.51 | $-0.67 |
| EBITDA | -$70M | -$68M | -$52M | -$49M | -$63M |
| Shares Outstanding | 75M | 84M | 85M | 100M | 101M |